DOCSLIB.ORG

ASCO 2017 Investor Event

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ASCO 2017 Investor Event ASCO 2017 Investor Event June 4, 2017 NOT FOR PRODUCT PROMOTIONAL USE 1 Forward-Looking Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This presentation also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com. NOT FOR PRODUCT PROMOTIONAL USE 2 BMS R&D Dr. Tom Lynch Chief Scientific Officer NOT FOR PRODUCT PROMOTIONAL USE 3 VISION FOR R&D We are focused, science oriented and data driven – and determined to deliver medicines that have the potential to transform the lives of patients NOT FOR PRODUCT PROMOTIONAL USE 4 R&D Priorities Expand Opdivo/Yervoy across multiple tumors/biomarker sets Accelerate delivery of our next wave of I-O assets Understand the biology of I-O resistance Develop novel combination regimens Accelerate development of our most promising assets in CFI Focus on Business Development NOT FOR PRODUCT PROMOTIONAL USE 5 Continued Immuno-Oncology R&D Success Positive Registrational 10 15 Trials 11 8 Approved Phase III trials Indications 6 stopped early 5 due to survival 4 benefit 15 in 2 Years Tumors with 2 ongoing registrational 0 trials Opdivo Avastin Taxotere New England Journal of Medicine Global Approvals 11 Publications Breakthrough ~250 for Opdivo Therapy 7 Designations Note: All milestones since 2014 NOT FOR PRODUCT PROMOTIONAL USE 6 Significant progress has been made, but the journey is only just beginning MECHANISMS PD-1 + What is next in the journey? Novel I-O LAG-3 Mechanisms PD-1/CTLA-4 combo IDO Novel Quads Combinations Triplets PD-1/ LIRI CTLA-4 chemo Vaccines/Viruses RT Targeted PD-1 combo GITR Non-IO mechanisms 2010 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16 ‘17 ‘18 ‘19 2020 ‘21 ‘22 ‘23 ‘24 ‘25 ‘26 ‘27 ‘28 ‘29 2030 NOT FOR PRODUCT PROMOTIONAL USE 7 Significant progress has been made, but the journey is only just beginning BIOMARKERS What is next in the journey? TMB* Gene signatures* PDL-1 LAG-3* Immunologic biomarkers* MSI-H Tumor derived markers* 2010 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16 ‘17 ‘18 ‘19 2020 ‘21 ‘22 ‘23 ‘24 ‘25 ‘26 ‘27 ‘28 ‘29 2030 *Exploratory/unapproved biomarkers NOT FOR PRODUCT PROMOTIONAL USE 8 BMS R&D Priorities in Oncology Leveraging Translational Approaches and Innovative Trial Designs • Improve outcomes for patients with: • Deliver on current O+/-Y development portfolio • IO sensitive tumors • Accelerate next wave of IO • Primary Resistance agents • Acquired Resistance • Explore new combination regimens NOT FOR PRODUCT PROMOTIONAL USE 9 Focus On Building Key Capabilities Enhance Translational Invest in Cancer Invest in Data Medicine Capabilities Biology and Analytics NOT FOR PRODUCT PROMOTIONAL USE 10 Our Industry Leading Internal Oncology Pipeline Anti-CTLA-4 NF Cabiralizumab Anti-LAG3 (Anti-CSF1R) Glypican-3 ADC Anti-GITR IDO Inhibitor Anti-TIGIT Ulocuplumab PROSTVAC (Anti-CXCR4) th Anti-CD73 Mesothelin ADC EMPLICITI Data as of May 10 , 2017 Marketed 1 Urelumab Anti-OX40 2 (Anti-CD137) OPDIVO Phase III Phase II Anti-Fucosyl HuMax-IL8 YERVOY Phase I GM1 Lirilumab 1 Approved in at least one BET Inhibitor SPRYCEL major market (Anti-KIR) (US, EU, JP) 2 In Ph III or currently under reg. review NOT FOR PRODUCT PROMOTIONAL USE 11 Data as of April 1, 2017 Oncology – Development Portfolio Phase I Phase II Phase III Approved Indications Anti-LAG3* + Anti-CTLA-4 NF ^ Mesothelin-ADC ^ OPDIVO* OPDIVO* OPDIVO* + YERVOY* OPDIVO* OPDIVO* OPDIVO* Solid Tumors Solid Tumors NHL (FL) Adjuvant Melanoma 1L Head & Neck Previously treated BRAF wild-type Met Solid Tumors Met Melanoma Melanoma OPDIVO* OPDIVO* + YERVOY* Glypican-3 ADC ^ BET Inhibitor OPDIVO* Lirilumab* 2L SCLC 1L Head & Neck OPDIVO* OPDIVO* + YERVOY* HCC Solid Tumors NHL (DLBCL) Hematologic Mal. 1L BRAF wild-type Melanoma across OPDIVO* + YERVOY* OPDIVO*# Met Melanoma BRAF status Anti-TIGIT ^ Ulocuplumab OPDIVO* Urelumab*+OPDIVO* 1L SCLC 3L Gastric Solid Tumors & OPDIVO* Solid Tumors Hematologic Mal. MSI+ Colon YERVOY* Hematologic Mal. Melanoma across OPDIVO* + YERVOY* OPDIVO* + YERVOY* Metastatic Melanoma 1L NSCLC 1L Gastric BRAF status Anti-GITR ^ Lirilumab*^ OPDIVO*# Anti-Fucosyl GM1 ^ Solid Tumors Solid Tumors # OPDIVO* Ovarian SCLC OPDIVO* OPDIVO* + YERVOY* Previously treated Unresectable NSCLC Adjuvant Gastric Adjuvant Melanoma Lirilumab* + EMPLICITI Met Squamous NSCLC Cabiralizumab*^ OPDIVO* EMPLICITI* 1L MM Pomalido- OPDIVO* OPDIVO*# Solid Tumors 2L HCC OPDIVO* EMPLICITI* MM mide Combo NSCLC Neoadjuvant 2L Esophageal Previously treated Met Relapsed/Refractory Anti-CD73 ^ Urelumab* + Non-squamous NSCLC MM Revlimid Combo EMPLICITI* OPDIVO* YERVOY OPDIVO* + YERVOY* OPDIVO* + YERVOY* Solid Tumors CNS Lymphoma Adolescent Mel NSCLC EGFR mutant MM 1L Esophageal OPDIVO* SPRYCEL* OPDIVO* OPDIVO* Previously treated Anti-OX40 ^ OPDIVO* + YERVOY* 1L CML Solid Tumors & SPRYCEL* Adjuvant Esophageal advanced RCC Solid Tumors 1L RCC Hematologic Mal. Pediatric /Gastroesophageal OPDIVO* SPRYCEL* Anti-LAG3*^ OPDIVO* + * Development Partnership OPDIVO* OPDIVO* + YERVOY* Advanced Hodgkin Refractory CML Solid Tumors & YERVOY EMPLICITI: AbbVie 1L Glioblastoma 1L Mesothelioma Lymphoma Hematologic Mal. Solid Tumors SPRYCEL: Otsuka OPDIVO* + OPDIVO, YERVOY: Ono Pharmaceutical OPDIVO* EMPLICITI* OPDIVO* OPDIVO* IDO Inhibitor ^ OPDIVO* Previously treated Prostvac: Bavarian Nordic 1L HCC Multiple Myeloma Previously treated Solid Tumors Pediatric Met Urothelial EMPLICITI* Met Head & Neck Lirilumab: Innate Pharma, Ono Pharmaceutical OPDIVO* Urelumab, Anti-LAG-3: Ono Pharmaceutical 1L MM Revlimid HuMax-IL8 Adjuvant Bladder Combo Solid Tumors Cabiralizumab: Five Prime Therapeutics OPDIVO* + YERVOY* PROSTVAC* ++ ^ Trial(s) exploring various combinations 1L Bladder Met CRPC Anti-CTLA-4 NF started a Phase 1 trial # Partner-run study and was added to this slide May 10 ++ Option rights NOT FOR PRODUCT PROMOTIONAL USE 12 Early Stage Pipeline Strategy D r. David Feltquate Head of Early Clinical Development NOT FOR PRODUCT PROMOTIONAL USE 13 The Immuno-Biology TUMOR The TUMOR may leverage of Cancer is Complex inherent mechanisms to • Effector cells are central for sustain itself and evade tumor recognition and killing immune destruction • Other factors may modulate the activity of effector cells The STROMA comprises a variety of cell types that may suppress immune function via EFFECTOR expression of cell surface or IMMUNE REGULATORY and CELL soluble inhibitory molecules, ANTIGEN-PRESENTING CELLS including metabolites may negatively regulate or not provide necessary stimulation to the immune system STROMA IMMUNE REGULATORY & APCs NOT FOR PRODUCT PROMOTIONAL USE 14 TUMOR Our Portfolio has Inhibit/target multiple approaches tumor cell pathways Fucosyl-GM1 BCR-ABL in each of these Glypican-3-ADC CXCR4 Activate T effector cells Mesothelin-ADC BET categories GITR CD137 OX40 ICOS BlockBlock tumor tumor inhibition/ checkpoints Maximize NK cells checkpoints PD-1 CTLA4 KIR SLAMF7 PD-1 CTLA4 TIM3TIM3 TIGITTIGIT BlockBlock or depleteor deplete LAG3 immune regulators LAG3 immune regulators EFFECTOR Block inhibitory IDO CSF1R CELL stromal effects IDOCD73CSF1RCTLA4-NF CD73 CTLA4-NF CCR2/5 IL-8 Optimize antigen STROMA presentation Vaccine IMMUNE Oncolytic Virus REGULATORY Radiation* & APCs Chemotherapy* NOT FOR PRODUCT PROMOTIONAL USE *Not part of BMY portfolio 15 Role of LAG-3 in T-Cell Exhaustion and Anti–PD-1 Resistance: Rationale For Anti–LAG-3 and Anti–PD-1 Combination Therapy + Nivolumab + Anti-LAG-3 Tumor or IO-Naïve: Other Infiltrating Cell In therapy-naïve patients, PD-1 PD-L1 LAG-3 limits IO response constitutive LAG-3 expression may limit the anti-tumor activity of PD-1 pathway blockade. LAG-3 MHC II Effector CD4+/CD8+ + Antigen PD-L1 T cell MHC II + Nivolumab + Anti-LAG-3 PD-1 PD-1 LAG-3 + Nivolumab In patients exposed to PD-1 pathway blockade, adaptive IO-Relapsed/Refractory: Acquires upregulation of LAG-3 expression resistance LAG-3 contributes to resistance may lead to treatment resistance and tumor progression. Nivolumab + Anti-LAG-3 (BMS-986016) NOT FOR PRODUCT PROMOTIONAL USE 16 Developing Biomarkers to Predict Better Outcomes Tumor Antigens Inflamed Tumor Microenvironment • Tumor Mutation Burden (TMB) • PD-L1 • Microsatellite Instability / • Tumor Inflammatory Signature Mismatch Repair Deficiency Tumor Inflamed (TIS) • T cell Receptor Profiling Antigens Tumor • T cell Infiltration Tumor Immune Suppression Host Environment Tumor Immune • Tim-3 Suppression • Microbiome Markers • LAG-3 • Suppressive Immune Cells (e.g. T-regs) NOT FOR PRODUCT PROMOTIONAL USE 17 Tumors with high mutation burden are a rational target for I-O therapy Tumor cells with …may have high …which can lead to high high TMB…1,2 neoantigen load…1,2 tumor immunogenicity and increased T-cell reactivity and anti-tumor response2-5 Mutated DNA NK cell CD8+ T cell Tumor Tumor cell The high immunogenicity of tumors with high mutation burden makes them a rational target for treatment with I-O therapies1,2 1. Schumacher TN, Schreiber RD. Science. 2015;348(6230):69-74. 2. Kim JM, Chen DS. Ann Oncol. 2016;27(8):1492-1504. 3. Liontos M et al. Ann Transl Med. 2016; 4(14):264. 4. Sharma P, Allison JP. Science. 2015;348(6230):56-61. 5. Giannakis M et al. Cell Rep.
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
    Review Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions Shilpa Gupta 1,†, David Gill 2,†, Austin Poole 2 and Neeraj Agarwal 2,* 1 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] 2 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; [email protected] (D.G.); [email protected] (A.P.) * Correspondence: [email protected]; Tel.: +1-801-213-5658; Fax: +1-801-585-0124 † These authors contributed equally to this work. Academic Editor: Vita Golubovskaya Received: 14 December 2016; Accepted: 18 January 2017; Published: 27 January 2017 Abstract: Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. While the role of immunotherapy was first established in non-muscle invasive bladder cancer in the 1970s, no systemic immunotherapy was approved for advanced disease until the recent approval of a programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, in patients with advanced/metastatic UC who have progressed on platinum-containing regimens. This represents a significant milestone in this disease after a void of over 30 years. In addition to atezolizumab, a variety of checkpoint inhibitors have shown a significant activity in advanced/metastatic urothelial carcinoma and are expected to gain Food and Drug Administration (FDA) approval in the near future.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Table S1. Medications Searched in Institutional Database Query Immune Checkpoint Inhibitors Additional Immune Modulators Atezol
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Table S1. Medications Searched in Institutional Database Query Immune Checkpoint Inhibitors Additional Immune Modulators Atezolizumab Abatacept Avelumab Adalimumab Cemiplimab Anakinra Durvalumab Belatacept Ipilimumab Certolizumab Lirilumab Cyclophosphamide Mogamulizumab Etanercept Nivolumab Golimumab Pembrolizumab Immune globulin IV Tremelimumab Infliximab Urelumab Mycophenolate mofetil Varlilumab Rituximab Tocilizumab Vedolizumab Beattie J, et al. J Immunother Cancer 2021; 9:e001884. doi: 10.1136/jitc-2020-001884 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Table S2. Toxicity of additional immune modulators Treatment detail Toxicity Patient 1 day 18,32 Infliximab dosed day 59 P.aeruginosa, S.marcescens pneumonia; died Patient 2 day 9 Infliximab dosed day 44 Febrile neutropenia; P. aeruginosa SBP and day 26 Mycophenolate initiated sepsis; C. albicans fungemia; treated and discharged Patient 8 day 4,11 Infliximab dosed day 14 Disseminated HSV-1; died Patient 26 day 79-128 Infliximab dosed (x7) day 130 E. faecalis, P. aeruginosa bacteremia; died; day 81, 97 Cyclophosphamide dosed Fungal pneumonia on autopsy Beattie J, et al. J Immunother Cancer 2021; 9:e001884. doi: 10.1136/jitc-2020-001884 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Table S3.
    [Show full text]
  • On the Horizon: Immuno-Oncology (I-O) Combinations
    Immuno-Oncology (I-O) Combinations • Jeffrey A. Sosman, MD • Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Cancer–Immunity Cycle Daniel Chen and Ira Mellman Immunity, Volume 39, Issue 1, 2013, 1 - 10 The Cancer–Immunity Cycle Daniel Chen and Ira Mellman Immunity, Volume 39, Issue 1, 2013, 1 - 10 Stimulatory and Inhibitory Factors in the Cancer-Immunity Cycle Each step of the Cancer-Immunity Cycle requires the coordination of numerous factors, both stimulatory and inhibitory in nature. Stimulatory factors shown in green promote immunity, ... Where will Improvements come from? • Combinations: – Based on Template: anti-PD-1/PD-L1 or with anti-PD- 1/anti-CTLA-4 • Block other co-inhibitory: LAG3, TIM3, KIR, VISTA • Activate co-stimulatory: 4-1BB, OX-40, GITR, CD27, ICOS • Block inhibitory molecules- IDOi, TGFbi, CSF1Ri, anti-IL-6 or anti- IL-10 • Effect trafficking- anti-VEGF, CCL5, CXCR4i • Vaccines- TVEC- oncolytic virus, Neoantigen, other cellular • Adoptive Cellular therapy- TIL, CAR-T cells, TCR T-cells Where will Improvements come from? • Combinations: – Based on Template: anti-PD-1/PD-L1 or with anti-PD- 1/anti-CTLA-4 • Signal Inhibition, BRAF directed (BRAFi+MEKi), MEKi, PI3K inhibition (PTEN effects) • Cytokines- IL-2, IFN a,b,g,, Directed cytokines (FAP-IL-2v or CEA-IL-2v) • Epigenetic modulation- gene expression and EVR expression • Microbiome modification- fecal transplants • Chemotherapy other cytotoxics • Localized Irradiation SBRT, SRS T cells in Tumors Express Multiple Immunoinhibitory Receptors
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • The Evolving Landscape of `Next-Generation' Immune
    European Journal of Cancer 117 (2019) 14e31 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.ejcancer.com Review The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review Luca Mazzarella a, Bruno Achutti Duso a, Dario Trapani a,b, Carmen Belli a, Paolo D’Amico a,b, Emanuela Ferraro a,b, Giulia Viale a,b, Giuseppe Curigliano a,b,* a New Drugs and Early Drug Development for Innovative Therapies Division, IEO, European Institute of Oncology IRCCS, Milan, Italy b University of Milano, Department of Hematology and Hemato-Oncology, Italy Received 17 March 2019; received in revised form 23 April 2019; accepted 26 April 2019 Available online 21 June 2019 KEYWORDS Abstract ‘First-generation’ immune checkpoint inhibitors targeting Cytotoxic T-Lympho- Next generation cyte Antigen 4 (CTLA4) and Programmed death-ligand 1 (PD(L)1) have undoubtedly revolu- immune-checkpoints; tionised the treatment of multiple cancers in the advanced setting. Targeting signalling LAG3; pathways other than core inhibitory modules may strongly impact the outcome of the antitu- TIGIT; mour immune response. Drugs targeting these pathways (‘next-generation’ immune modula- TIM3; tors, NGIMs) constitute a major frontier in translational research and have generated 4-1BB; unprecedented scientific and financial investment. Here, we systematically reviewed published IDO1; literature, abstracts from major cancer conferences and pharma pipelines to identify NGIMs GITR; that have reached clinical development. We identified 107 molecules targeting 16 pathways, Colony stimulating which we classified into 6 groups according to function (inhibitory vs stimulatory) and cell factor-1 (CSF-1) of predominant expression (lymphoid, non-lymphoid and natural killer).
    [Show full text]
  • Intratumoral Immunization: a New Paradigm for Cancer Therapy
    Clinical Cancer Review Research Intratumoral Immunization: A New Paradigm for Cancer Therapy Aurelien Marabelle1, Holbrook Kohrt2, Christophe Caux1, and Ronald Levy2 Abstract Immune cell infiltration in the tumor microenvironment is of prognostic and therapeutic import. These immune cell subsets can be heterogeneous and are composed of mature antigen-presenting cells, helper and effector cytotoxic T cells, toleragenic dendritic cells, tumor-associated macrophages, and regulatory T cells, among other cell types. With the development of novel drugs that target the immune system rather than the cancer cells, the tumor immune microenvironment is not only prognostic for overall patient outcome, but also predictive for likelihood of response to these immune-targeted therapies. Such therapies aim to reverse the cancer immunotolerance and trigger an effective antitumor immune response. Two major families of immunostimulatory drugs are currently in clinical development: pattern recognition receptor agonists (PRRago) and immunostimulatory monoclonal antibodies (ISmAb). Despite their immune-targeted design, these agents have so far been developed clinically as if they were typical anticancer drugs. Here, we review the limitations of this conventional approach, specifically addressing the shortcomings of the usual schedules of intravenous infusions every 2 or 3 weeks. If the new modalities of immunotherapy target specific immune cells within the tumor microenvironment, it might be preferable to deliver them locally into the tumor rather than systemically. There is preclinical and clinical evidence that a therapeutic systemic antitumor immune response can be generated upon intratumoral immunomodulation. Moreover, pre- clinical results have shown that therapeutic synergy can be obtained by combining PRRagos and ISmAbs to the local tumor site.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Natural Killer Cell-Based Immunotherapy for Acute Myeloid Leukemia
    Xu and Niu J Hematol Oncol (2020) 13:167 https://doi.org/10.1186/s13045-020-00996-x REVIEW Open Access Natural killer cell-based immunotherapy for acute myeloid leukemia Jing Xu and Ting Niu* Abstract Despite considerable progress has been achieved in the treatment of acute myeloid leukemia over the past decades, relapse remains a major problem. Novel therapeutic options aimed at attaining minimal residual disease-negative complete remission are expected to reduce the incidence of relapse and prolong survival. Natural killer cell-based immunotherapy is put forward as an option to tackle the unmet clinical needs. There have been an increasing num- ber of therapeutic dimensions ranging from adoptive NK cell transfer, chimeric antigen receptor-modifed NK cells, antibodies, cytokines to immunomodulatory drugs. In this review, we will summarize diferent forms of NK cell-based immunotherapy for AML based on preclinical investigations and clinical trials. Keywords: Acute myeloid leukemia, Natural killer cells, Immunotherapy, Adoptive NK cell transfer, Chimeric antigen receptor-modifed NK cells, Antibodies, Cytokines Background cells and substances in the immune system play pivotal Acute myeloid leukemia (AML) is a clinically and geneti- roles in detecting and destroying pathogen-infected or cally heterogeneous disease with unsatisfactory out- neoplastically transformed cells. But they become less comes. Over the last few years, considerable progress has potent in cancer elimination when malignant cells dis- been achieved in the treatment of AML with the devel- play the loss of antigenicity and/or immunogenicity and opment and implementation of new drugs [1, 2]. How- are surrounded by an immunosuppressive microenvi- ever, allogeneic hematopoietic cell transplantation (HCT) ronment [6].
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]